Method for the suppression of visceral pain by regulating T type calcium channel

Abstract

The disclosure concerns a method for the suppression of visceral pain by regulating the T-type calcium channel; a visceral pain inhibitor that includes a T-type calcium channel inhibitor as an effective ingredient; and a method of screening a visceral pain inhibitor by investigating the suppression activity of T-type calcium channels. Particularly, the present invention relates to a method for the suppression of visceral pain by regulating an alpha 1G T-type calcium channel in the central nervous system and alpha 1H and alpha 1I T-type calcium channels in the peripheral nervous system; a visceral pain inhibitor that includes a T-type calcium channel inhibitor as an effective ingredient; and a method of screening a visceral pain inhibitor by investigating the suppression activity of T-type calcium channels. The method of the present invention can be effectively used to suppress visceral pain by regulating T-type calcium channel in a precise mechanism without any side effects.

What is claimed is:  
     
         1 . A method for the suppression of visceral pain by regulating the T-type calcium channel.  
     
     
         2 . The method as set forth in  claim 1 , wherein the T-type calcium channel is selected from a group consisting of alpha 1G, alpha 1H and alpha 1I T-type calcium channels.  
     
     
         3 . The method as set forth in  claim 1 , wherein the suppression of visceral pain is achieved by activating the function of alpha 1G T-type calcium channel in the central nervous system.  
     
     
         4 . The method as set forth in  claim 1 , wherein the suppression of visceral pain is achieved by inhibiting the function of alpha 1H and alpha 1I T-type calcium channels in the peripheral nervous system.  
     
     
         5 . A visceral pain inhibitor containing the T-type calcium channel inhibitor as an effective ingredient.  
     
     
         6 . The visceral pain inhibitor as set forth in claim 5, wherein the T-type calcium channel is alpha 1H or alpha 1I T-type calcium channel.  
     
     
         7 . The visceral pain inhibitor as set forth in claim 5, wherein the T-type calcium channel inhibitor is selected from a group consisting of mibefradil and Ni 2+ .  
     
     
         8 . A screening method of the visceral pain inhibitor by investigating the suppression activity of the T-type calcium channel.